Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preemptive Analgesia in Cruciate Reconstruction

This study has been completed.
Information provided by:
Prince of Songkla University Identifier:
First received: November 17, 2009
Last updated: November 19, 2009
Last verified: November 2009

The aims of this study was to compare analgesic efficacy of preoperative administration of etoricoxib versus celecoxib for post-operative pain relief after arthroscopic anterior cruciate ligament reconstruction. One hundred and two patients diagnosed as anterior cruciate ligament injury will randomized into 3 groups using opaque envelope. Both patients and surgeon were blinded to the allocation. All of the patients will be operated by one orthopaedic surgeon under regional anesthesia. Each group will be given either etoricoxib 120 mg., celecoxib 400 mg., or placebo 1 hour prior to operative incision. Post-operative pain intensity, time to first dose of analgesic requirement and numbers of analgesic used for rescue pain control and adverse events will be recorded periodically to 48 hours after surgery.

Condition Intervention Phase
Anterior Cruciate Ligament Injury
Drug: Celecoxib
Drug: etoricoxib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparing Etoricoxib and Celecoxib for Preemptive Analgesia for Acute Postoperative Pain in Patients Undergoing Arthroscopic Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by Prince of Songkla University:

Primary Outcome Measures:
  • VAS score [ Time Frame: 6,12,24,48 hour postoperative ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • number of analgesic used [ Time Frame: 48 hour postoperative ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: January 2008
Study Completion Date: June 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: placebo
identical placebo
Drug: Celecoxib
celecoxib 400 mg 1 cap before surgery
Drug: etoricoxib
120 mg 1 tab before surgery


Ages Eligible for Study:   15 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with anterior cruciate ligament injury age 15-50 yr

Exclusion Criteria:

  • previous knee surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01017380

Prince of Songkla University
Hat Yai, Songkhla, Thailand, 90110
Sponsors and Collaborators
Prince of Songkla University
Study Director: Boonsin Tangtrakulwanich, MD.,Ph.D Faculty of Medicine, Prince of Songkla University
  More Information

No publications provided by Prince of Songkla University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Secretariate,Department of Orthopaedic Surgery, Facuty of Medicine, Prince of Songkla University Identifier: NCT01017380     History of Changes
Other Study ID Numbers: EC50/369-007
Study First Received: November 17, 2009
Last Updated: November 19, 2009
Health Authority: Thailand: Ethical Committee

Keywords provided by Prince of Songkla University:
preemptive analgesia
cruciate ligament processed this record on March 03, 2015